INDP

Indaptus Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website indaptusrx.com
Employees(FY) 6
ISIN US45339J1051

Performance

-7.13%

-8.93%

-37.47%

-62.33%

-46.7%

YTD

-49.02%

Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of INDP 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 31 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of INDP

Stock Rank

Recent News & Updates

2024-11-21 19:36
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement(Globenewswire)
2024-11-11 19:00
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-11-10 19:00
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology(Globenewswire)
2024-11-06 19:00
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting(Globenewswire)
2024-10-22 20:00
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences(Globenewswire)
2024-10-21 20:00
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations(Globenewswire)
2024-10-14 20:00
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data(Globenewswire)
2024-10-09 20:00
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy(Globenewswire)
2024-10-07 20:00
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-04 20:30
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses(Globenewswire)
2024-09-02 20:00
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-11 20:00
Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-08-06 19:00
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement(Globenewswire)
2024-06-10 20:00
Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit(Globenewswire)
2024-06-03 20:00
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference(Globenewswire)
2024-06-02 20:00
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20(Globenewswire)
2024-05-29 20:00
Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-28 20:00
Indaptus Therapeutics to Present New Cohort Data Confirming Original Pulse-Prime Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting(Globenewswire)
2024-05-21 20:00
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company's Broad-Based, Pulse-Prime Immuno-Oncology Therapy for Advanced Solid Tumors(Globenewswire)
2024-05-08 00:54
INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-07 20:00
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-04-10 19:30
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting(Globenewswire)
2024-03-27 20:00
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference(Globenewswire)
2024-03-24 20:30
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting(Globenewswire)
2024-03-17 20:00
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024(Globenewswire)
2024-03-12 19:30
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-03-03 18:30
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort(Globenewswire)
2024-02-14 19:00
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference(Globenewswire)
2024-02-07 19:00
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels(Globenewswire)
2024-01-03 19:00
European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.